Research ArticleArticle
Cytochrome P450 Inhibitory Properties of Common Efflux Transporter Inhibitors
Gunilla Englund, Patrik Lundquist, Cristine Skogastierna, Jenny Johansson, Janet Hoogstraate, Lovisa Afzelius, Tommy B. Andersson and Denis Projean
Drug Metabolism and Disposition March 2014, 42 (3) 441-447; DOI: https://doi.org/10.1124/dmd.113.054932
Gunilla Englund
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje (G.E., P.L., C.S., J.J., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal (P.L., T.B.A., D.P.); Department of Pharmacy, Uppsala University, Uppsala (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (T.B.A.), Sweden
Patrik Lundquist
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje (G.E., P.L., C.S., J.J., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal (P.L., T.B.A., D.P.); Department of Pharmacy, Uppsala University, Uppsala (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (T.B.A.), Sweden
Cristine Skogastierna
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje (G.E., P.L., C.S., J.J., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal (P.L., T.B.A., D.P.); Department of Pharmacy, Uppsala University, Uppsala (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (T.B.A.), Sweden
Jenny Johansson
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje (G.E., P.L., C.S., J.J., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal (P.L., T.B.A., D.P.); Department of Pharmacy, Uppsala University, Uppsala (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (T.B.A.), Sweden
Janet Hoogstraate
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje (G.E., P.L., C.S., J.J., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal (P.L., T.B.A., D.P.); Department of Pharmacy, Uppsala University, Uppsala (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (T.B.A.), Sweden
Lovisa Afzelius
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje (G.E., P.L., C.S., J.J., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal (P.L., T.B.A., D.P.); Department of Pharmacy, Uppsala University, Uppsala (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (T.B.A.), Sweden
Tommy B. Andersson
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje (G.E., P.L., C.S., J.J., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal (P.L., T.B.A., D.P.); Department of Pharmacy, Uppsala University, Uppsala (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (T.B.A.), Sweden
Denis Projean
CNS and Pain Innovative Medicines DMPK, AstraZeneca R&D, Södertälje (G.E., P.L., C.S., J.J., J.H., L.A.); Cardiovascular and Metabolic Diseases Innovative Medicines DMPK, AstraZeneca R&D, Mölndal (P.L., T.B.A., D.P.); Department of Pharmacy, Uppsala University, Uppsala (P.L.); and Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm (T.B.A.), Sweden

Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
P450 Inhibition by Efflux Transporter Inhibitors
Gunilla Englund, Patrik Lundquist, Cristine Skogastierna, Jenny Johansson, Janet Hoogstraate, Lovisa Afzelius, Tommy B. Andersson and Denis Projean
Drug Metabolism and Disposition March 1, 2014, 42 (3) 441-447; DOI: https://doi.org/10.1124/dmd.113.054932
Research ArticleArticle
P450 Inhibition by Efflux Transporter Inhibitors
Gunilla Englund, Patrik Lundquist, Cristine Skogastierna, Jenny Johansson, Janet Hoogstraate, Lovisa Afzelius, Tommy B. Andersson and Denis Projean
Drug Metabolism and Disposition March 1, 2014, 42 (3) 441-447; DOI: https://doi.org/10.1124/dmd.113.054932